Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Phylogica Announces Changes to Board and Management (ASX:PYC)

Alan Tribe appointed as Chair of the Board of Directors and acquires 19.9% shareholding in Phylogica Rohan Hockings appointed as Chief Executive Officer Stephanie Unwin resigns as Chair and C...read more

Phylogica Limited announces Cre Enzyme Delivery Provides Validation & Strategic Value (ASX:PYC)

Phylogica Limited (ASX:PYC) announces Cre Enzyme Delivery Provides Validation & Strategic Value PERTH, Australia, 2 March 2018: Phylogica Limited (ASX:PYC) (Phylogica or the Company), developer...read more

Phylogica Limited announces Dec 2017 Half-year financial statements & Appendix 4D (ASX:PYC)

Phylogica Limited (ASX:PYC) Dec 2017 Half-year financial statements & Appendix 4D. To view the report please download PDF attached:

Phylogica Announces Operational Update and Conference Call - December Quarter (ASX:PYC)

PERTH, Australia, 31 January 2018: Phylogica Limited (ASX:PYC) (Phylogica or the Company), developer of a leading intracellular drug delivery platform technology, is pleased to update shareholders on ...read more

Phylogica Announces New Scientific Advisory Board Member Appointed (ASX:PYC)

PERTH, Australia, 12 January 2018: Phylogica Limited (ASX:PYC) (Phylogica or the Company), developer of a leading intracellular drug delivery platform technology, is pleased to announce the appointmen...read more

Phylogica Announces Federal R&D Tax Credit Received (ASX:PYC)

PERTH, Australia, 11th January 2018: Phylogica Limited (ASX:PYC) (Phylogica or the Company), advises that it has received a $2,170,000 cash refund under the Federal Government’s R&D Tax Ince...read more

Phylogica, Pivot to Platform - BioShowcase Presentation (ASX:PYC)

Pivot from developing drugs to commercialising the platform Value proposition: Enhance existing drugs to address a massive 250B USD (CAGR 10.6%) market 1. Bring drugs to the right place (i.e. to...read more

Phylogica Announces FPP Effective in Delivering Peptide Cancer Vaccine (ASX:PYC)

Immunotherapy – animal model results show FPP effective in delivering peptide cancer vaccine – patent filing Phylogica’s Functional Penetrating Peptide (FPP) conjugated to a tumo...read more

Phylogica, Appendix 3B and Appendix 3Y (ASX:PYC)

PERTH, Australia, 5th January 2018: Phylogica Limited (ASX:PYC) (Phylogica or the Company), submits the following Appendices in relation to the issue of shares upon the exercise of options: Appendi...read more

Phylogica Announces Appointment of Non-Executive Director (ASX:PYC)

PERTH, Australia, 3 January 2018: Phylogica Limited (ASX:PYC) (Phylogica or the Company), developer of a leading intracellular drug development and delivery platform technology, is pleased to announce...read more

Phylogica Announces Strategic Update - 'Pivot to Platform' (ASX:PYC)

PERTH, Australia, 4th December 2017: Phylogica Limited (ASX:PYC) (Phylogica or the Company), developer of a leading intracellular drug delivery platform technology, is pleased to provide a strategic u...read more

Phylogica, Final Director's Interest Notice (ASX:PYC)

Appendix 3Z Paul Watt To view Notice please download PDF attached:

Phylogica, Appendix 3B and 3Y's (ASX:PYC)

PERTH, Australia, 30th November 2017: Phylogica Limited (ASX:PYC) (Phylogica or the Company), submits the following Appendices in relation to the issue of related party options, as approved by shareho...read more

Phylogica, Company Presentation - 2017 Annual General Meeting (ASX:PYC)

We must pivot from developing drugs to commercialising the platform Value proposition: Enhance existing drugs to address a large and growing $250Bn USD market 1. Bring drugs to the right place (...read more

Phylogica, Chairman's Address - 2017 Annual General Meeting (ASX:PYC)

PERTH, Australia, 27th November 2017: Phylogica Limited (ASX:PYC) (Phylogica or the Company), provides the Chairman’s Address from the 2017 Annual General Meeting CHAIRMAN’S ADDRESS ...read more

Viewing: 31 - 45 of 116 Previous | Next